Maui Derm Conferences

This interview with Culton featured a discussion of key challenges faced when treating patients with blistering diseases such as pemphigus and bullous pemphigoid.

In this segment of his interview, Zirwas highlighted the use of JAK inhibitors such as upadacitinib, discussed safety, and touched on topical options for patients with eczema.

Shapiro spoke in his Maui Derm NP+PA Fall conference interview about differentiating between types of alopecia areata and about the potential use of JAK inhibitors.

Zirwas described several highlights from his presentation on updates in managing atopic dermatitis, describing examples such as lebrikizumab and nemolizumab.

In her Maui Derm NP+PA Fall interview, Harper highlighted treatment approaches and unmet needs of patients with acne.

In her Maui Derm NP+PA Fall conference presentation, Baldwin highlighted the latest information on approaches to treating rosacea.

After his review on recent literature, Zirwas’s Maui Derm NP+PA Fall interview featured a discussion about the biggest unmet needs among patients.

At Maui Derm NP+PA Fall 2024, bimekizumab data demonstrates a consistent safety profile in moderate to severe plaque psoriasis over 4 years, with decreasing event rates over time.

This interview featured a literature review discussion about non-FDA approved advancements in dermatology, including oral roflumilast for psoriasis, metformin for acne, and minoxidil for nails.

In this interview segment, Chovatiya highlights HS therapies such as IL-17 inhibitors and JAK inhibitors, as well as unmet needs of patients.

This interview with Chovatiya highlights promising therapies in the dermatology space for the treatment of patients with the skin condition HS.

In this Maui Derm fall conference session, Callender highlights approaches to pigmentation issues such as vitiligo, melasma, and other disorders.

These poster data highlight that atopic dermatitis treatment may be suboptimal in certain patients, demonstrating the necessity of additional effective therapy options.

Nemolizumab shows early and sustained benefits in reducing itch and sleep disturbance in moderate-to-severe atopic dermatitis, per ARCADIA data.

These real-world data resulted from an interim analysis of the PSoSA study on psoriasis patients with scalp itch, nail pain, and quality of life impairment.

These poster data presented at the Maui Derm Fall 2024 conference highlight changes in laboratory parameters for patients using the TYK2 inhibitor deucravacitinib.

This is an overview of our upcoming Maui Derm NP+PA Fall 2024 Program conference coverage.

Analysis of a novel form of the topical drug shows rosacea is benefitted within 2 weeks of daily administration.

An analysis of patients with psoriasis, PsA, or axSpA show risk of MACE with ixekizumab is consistently low.

Ritlecitinib becomes the second JAK inhibitor approved to treat alopecia—and the first to be indicated for patients aged 12 years and older.

Post hoc analysis of the topical therapy show patients receiving treatment for acne in the winter were as likely to achieve benefit as those receiving it in the summer.

A post hoc analysis of phase 3 adds support to the IL-17A inhibitor for the potential treatment of HS.

While contact dermatitis is difficult to distinguish in children, there has become a greater collaboration between allergic and dermatologic specialists in managing conditions like atopic dermatitis.

The first triple-combination topical drug for acne may be available by the end of this year. One expert has high hopes for it.

Zirwas touts topical ruxolitinib's rapid, effective treatment of atopic dermatitis, and reviews the safety outcomes associated with JAK inhibitors.

Pigmentary disorders including melasma are difficult to treat and complex. The leading agent for one expert was uncovered by unique circumstances.

From addressing the rare acne fulminans to utilizing narrow-spectrum antibiotics, the modern field of acne treatment is more complicated than it seems.

Analysis of phase 3 trial data show the JAK inhibitor is generally safe among patients with severe forms of the chronic hair loss disease.

In the span of a decade, agents like topical ivermectin, minocycline and benzoyl peroxide has provided more opportunities to achieve clear skin for rosacea patients.

The trial investigator reviews disparities in patient needs and treatment outcomes based on their skin complexion, 1 year after ruxolitinib's FDA approval.